Anika Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Anika Therapeutics
ANIK Stock  USD 10.21  0.15  1.49%   
Analyzing historical trends in various income statement and balance sheet accounts from Anika Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Anika Therapeutics' valuation are summarized below:
Gross Profit
62.4 M
Profit Margin
(0.29)
Market Capitalization
147.2 M
Enterprise Value Revenue
1.0097
Revenue
112.8 M
There are currently one hundred twenty fundamental signals for Anika Therapeutics that can be evaluated and compared over time across rivals. We recommend to validate Anika Therapeutics' prevailing fundamental drivers against the all of the trends between 2010 and 2026. Market Cap is expected to rise to about 608.3 M this year. Enterprise Value is expected to rise to about 539 M this year

Anika Therapeutics Total Revenue

144.79 Million

Check Anika Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anika Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.8 M, Interest Expense of 2.8 M or Selling General Administrative of 67.1 M, as well as many indicators such as Price To Sales Ratio of 3.32, Dividend Yield of 0.0 or PTB Ratio of 1.71. Anika financial statements analysis is a perfect complement when working with Anika Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Anika Stock
Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.

Anika Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets150.3 M233.2 M230.7 M
Slightly volatile
Short and Long Term Debt Total16 M29.8 M20.8 M
Slightly volatile
Total Current Liabilities28.1 M26.8 M18.6 M
Slightly volatile
Total Stockholder Equity122.4 M177.1 M193.2 M
Slightly volatile
Property Plant And Equipment Net78.1 M74.4 M53.9 M
Slightly volatile
Accounts Payable3.7 M6.5 M4.9 M
Slightly volatile
Cash54.9 M64 M80.2 M
Pretty Stable
Non Current Assets Total56.8 M102.5 M90.1 M
Slightly volatile
Cash And Short Term Investments62 M64 M91.1 M
Pretty Stable
Net Receivables28.5 M27.1 M22.7 M
Slightly volatile
Common Stock Shares Outstanding12.8 M16.9 M14 M
Slightly volatile
Liabilities And Stockholders Equity150.3 M233.2 M230.7 M
Slightly volatile
Non Current Liabilities Total15.7 M29.3 M19.9 M
Slightly volatile
Inventory28.7 M27.4 M21.4 M
Slightly volatile
Other Current Assets12.8 M12.2 M7.6 M
Slightly volatile
Other Stockholder Equity107.4 M102.3 M70 M
Slightly volatile
Total Liabilities58.9 M56.1 M39.3 M
Slightly volatile
Property Plant And Equipment Gross134 M127.6 M63.4 M
Slightly volatile
Total Current Assets93.6 M130.7 M140.6 M
Slightly volatile
Short Term Debt1.6 M2.2 M1.2 M
Slightly volatile
Non Currrent Assets Other16.4 M15.7 M8.5 M
Slightly volatile
Common Stock Total Equity139.2 K167.9 K142.7 K
Slightly volatile
Common Stock140.8 K165.6 K142.6 K
Slightly volatile
Property Plant Equipment32.3 M55.5 M42.6 M
Slightly volatile
Current Deferred Revenue1.4 M1.4 M4.8 M
Pretty Stable
Other Liabilities8.1 M6.2 M7.6 M
Slightly volatile
Good Will8 M8.2 M7.6 M
Pretty Stable
Intangible Assets2.7 M2.9 M22.7 M
Pretty Stable
Net Tangible Assets227.7 M267.3 M200.1 M
Slightly volatile
Long Term Debt Total7.7 M8.6 M9.4 M
Slightly volatile
Capital Surpluse52.5 M73 M68.4 M
Very volatile
Non Current Liabilities Other843.4 K887.8 K2.3 M
Very volatile
Net Invested Capital202.7 M138.6 M247.8 M
Slightly volatile
Net Working Capital125 M81.3 M165.3 M
Slightly volatile
Capital Stock158.6 K165.6 K145.2 K
Slightly volatile
Capital Lease Obligations27.2 M29.8 M24 M
Slightly volatile

Anika Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization9.8 M9.3 M7.4 M
Slightly volatile
Selling General Administrative67.1 M63.9 M39.4 M
Slightly volatile
Total Revenue144.8 M137.9 M106.3 M
Slightly volatile
Gross Profit91.8 M87.4 M70.5 M
Slightly volatile
Other Operating Expenses150.9 M143.8 M90.6 M
Slightly volatile
Cost Of Revenue53 M50.5 M35.8 M
Slightly volatile
Total Operating Expenses97.9 M93.3 M54.8 M
Slightly volatile
Research Development30.8 M29.4 M16.9 M
Slightly volatile
Interest Income2.3 M2.2 M1.1 M
Slightly volatile
Reconciled Depreciation11.1 M9.3 M7.7 M
Slightly volatile
Extraordinary Items1.8 M2.1 M2.3 M
Slightly volatile

Anika Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation9.8 M9.3 M7.5 M
Slightly volatile
Capital Expenditures9.3 M8.9 M5.4 M
Slightly volatile
End Period Cash Flow55.1 M65.7 M80.6 M
Pretty Stable
Begin Period Cash Flow54.9 M83.8 M80 M
Slightly volatile
Stock Based Compensation11.2 M11.8 M81.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.321.824.3659
Slightly volatile
PTB Ratio1.711.422.1515
Slightly volatile
Days Sales Outstanding55.2364.6478.5527
Pretty Stable
Book Value Per Share6.699.4113.2443
Slightly volatile
Average Payables2.4 M1.8 M2.3 M
Slightly volatile
Stock Based Compensation To Revenue0.120.132.8415
Slightly volatile
Capex To Depreciation1.041.11.1635
Slightly volatile
PB Ratio1.711.422.1515
Slightly volatile
EV To Sales2.61.63.602
Pretty Stable
Inventory Turnover1.471.661.7222
Slightly volatile
Days Of Inventory On Hand287228247
Very volatile
Payables Turnover6.157.047.5032
Pretty Stable
Sales General And Administrative To Revenue0.30.370.3018
Very volatile
Average Inventory11.1 M10.5 M10.6 M
Slightly volatile
Research And Ddevelopement To Revenue0.20.240.159
Slightly volatile
Capex To Revenue0.110.07420.0876
Slightly volatile
Cash Per Share3.483.46.2869
Very volatile
Days Payables Outstanding80.9453.765.7939
Pretty Stable
Intangibles To Total Assets0.05180.05450.1205
Pretty Stable
Current Ratio6.94.399.7155
Slightly volatile
Tangible Book Value Per Share5.668.8311.1184
Slightly volatile
Receivables Turnover7.215.844.9282
Pretty Stable
Shareholders Equity Per Share6.699.4113.2443
Slightly volatile
Debt To Equity0.130.190.105
Slightly volatile
Capex Per Share0.260.470.3604
Pretty Stable
Graham Net Net2.812.235.5225
Very volatile
Average Receivables17 M16.1 M17 M
Slightly volatile
Revenue Per Share7.77.336.983
Slightly volatile
Interest Debt Per Share0.861.591.3647
Slightly volatile
Debt To Assets0.09790.150.0836
Slightly volatile
Graham Number10.7110.2117.0444
Pretty Stable
Operating Cycle363310328
Very volatile
Price Book Value Ratio1.711.422.1515
Slightly volatile
Days Of Payables Outstanding80.9453.765.7939
Pretty Stable
Ebt Per Ebit0.870.491.1059
Pretty Stable
Company Equity Multiplier1.431.511.2447
Pretty Stable
Long Term Debt To Capitalization0.140.07870.0782
Very volatile
Total Debt To Capitalization0.120.170.095
Slightly volatile
Debt Equity Ratio0.130.190.105
Slightly volatile
Quick Ratio6.013.478.454
Slightly volatile
Cash Ratio4.132.155.8102
Slightly volatile
Cash Conversion Cycle282256262
Pretty Stable
Days Of Inventory Outstanding287228247
Very volatile
Days Of Sales Outstanding55.2364.6478.5527
Pretty Stable
Price To Book Ratio1.711.422.1515
Slightly volatile
Fixed Asset Turnover2.032.131.9977
Pretty Stable
Debt Ratio0.09790.150.0836
Slightly volatile
Price Sales Ratio3.321.824.3659
Slightly volatile
Asset Turnover0.480.680.4413
Slightly volatile
Gross Profit Margin0.460.570.6264
Very volatile
Price Fair Value1.711.422.1515
Slightly volatile

Anika Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap608.3 M579.3 M531.2 M
Slightly volatile
Enterprise Value539 M513.3 M466.7 M
Slightly volatile

Anika Fundamental Market Drivers

Forward Price Earnings39.3701
Cash And Short Term Investments55.6 M

Anika Upcoming Events

4th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Anika Therapeutics Financial Statements

Anika Therapeutics investors utilize fundamental indicators, such as revenue or net income, to predict how Anika Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue1.4 M1.4 M
Total Revenue137.9 M144.8 M
Cost Of Revenue50.5 M53 M
Stock Based Compensation To Revenue 0.13  0.12 
Sales General And Administrative To Revenue 0.37  0.30 
Research And Ddevelopement To Revenue 0.24  0.20 
Capex To Revenue 0.07  0.11 
Revenue Per Share 7.33  7.70 
Ebit Per Revenue(0.04)(0.04)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Anika Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Anika Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Anika Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Anika Therapeutics Stock:
How To Invest In Anika
Details
Is Anika Stock a good investment?
Details
What is Anika Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Anika Therapeutics Correlation against competitors.
For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.
You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Anika Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
(0.51)
Earnings Share
(0.99)
Revenue Per Share
7.826
Quarterly Revenue Growth
(0.06)
Return On Assets
(0.04)
Anika Therapeutics's market price often diverges from its book value, the accounting figure shown on Anika's balance sheet. Smart investors calculate Anika Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Anika Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Anika Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Anika Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY